home / stock / celg / celg quote
Last: | $ |
---|---|
Change Percent: | 0.88% |
Open: | $101.11 |
Close: | $101.86 |
High: | $102.02 |
Low: | $101.11 |
Volume: | 2,053,419 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $101.11 | $101.86 | $102.02 | $101.11 | 2,053,419 | 10-17-2019 |
$ | $100.64 | $100.97 | $101.22 | $100.50 | 3,221,244 | 10-16-2019 |
$ | $100.50 | $100.95 | $101.185 | $100.40 | 2,655,352 | 10-15-2019 |
$ | $100.53 | $100.39 | $100.66 | $100.1111 | 1,836,076 | 10-14-2019 |
$ | $100.25 | $100.57 | $100.96 | $99.98 | 3,698,436 | 10-11-2019 |
$ | $99.73 | $99.81 | $99.90 | $99.26 | 3,238,951 | 10-10-2019 |
$ | $99.04 | $99.63 | $99.86 | $99.03 | 2,979,581 | 10-09-2019 |
$ | $99.25 | $98.88 | $100.02 | $98.67 | 4,213,530 | 10-08-2019 |
$ | $99.63 | $99.70 | $100.42 | $99.56 | 3,627,720 | 10-07-2019 |
$ | $98.51 | $99.87 | $100.10 | $98.43 | 3,469,435 | 10-04-2019 |
$ | $97.51 | $98.42 | $98.43 | $97.34 | 3,784,489 | 10-03-2019 |
$ | $98.97 | $97.62 | $98.98 | $97.30 | 4,375,627 | 10-02-2019 |
$ | $99.51 | $99.26 | $100.19 | $99.05 | 4,202,619 | 10-01-2019 |
$ | $98.85 | $99.30 | $99.93 | $98.53 | 5,198,727 | 09-30-2019 |
$ | $98.68 | $98.85 | $99.25 | $98.44 | 4,643,178 | 09-27-2019 |
$ | $98.58 | $98.59 | $98.88 | $97.97 | 3,763,368 | 09-26-2019 |
$ | $98.62 | $98.56 | $99.05 | $98.37 | 2,900,832 | 09-25-2019 |
$ | $99.80 | $98.62 | $99.85 | $98.48 | 4,523,337 | 09-24-2019 |
$ | $99.45 | $99.42 | $99.81 | $99.31 | 3,128,528 | 09-23-2019 |
$ | $98.65 | $99.37 | $99.66 | $98.50 | 5,387,529 | 09-20-2019 |
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
0.88% G/L:
$ Last:
2,053,419 Volume:
$101.11 Open:
$101.86 Close:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...